Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Paul J. Bröckelmann, Ina Bühnen, Josée M Zijlstra, Stephan Mathas, Katrin S Roth, Maria Garcia-Marquez, Christian Sillaber, Julia Meissner, Alexander Fossa, Richard Greil, Karolin Trautmann-Grill, Johannes Rosenbrock, Wouter Plattel, Hans A Schlösser, Carsten Kobe, Michael Fuchs, Peter Borchmann, Christian Baues

Blood (2024) 144 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2024-202113

Published: 2024

Journal Articles

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Blood (2023) 142 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2023-188449

Published: 2023

Journal Articles

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Blood (2023) 142 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2023-181707

Published: 2023

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Improved Risk Prediction in DLBCL By Combining Clinical and PET Features with Interim PET Assessment

Christine Hanoun, Martijn Heymans, Sanne Wiegers, Annelies Bes, Ulrich Duehrsen, Andreas Huettmann, Lars Kurch, Sally F Barrington, George Mikhaeel, Pieternella Lugtenburg, Luca Ceriani, Emanuele Zucca, Tamas Gyorke, Sandor Czibor, Gerben Zwezerijnen, Ronald Boellaard, Josée M. Zijlstra, Corinne Eertink

Blood (2023) 142 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2023-190277

Published: 2023

Journal Articles

Important Role for Glutamine in Human and Mouse TME Models of CLL ; Towards Development of a PET Tracer As a Novel Diagnostic Tool

Helga Simon-Molas, Chiara Montironi, Gaspard Cretenet, Sjoerd P.P. van Eeden, Rosita Del Prete, Zhenghao Chen, Ingrid A.M. Derks, Mariska Verlaan, Arnon P. Kater, Wissam Beaino, Anna Kabanova, Josée M. Zijlstra, Albert D. Windhorst, Eric Eldering

Blood (2023) 142 (Supplement 1): 4622.

https://doi.org/10.1182/blood-2023-174853

Published: 2023

Journal Articles

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Dennis A. Eichenauer, Ina Bühnen, Christian Baues, Carsten Kobe, Helen Kaul, Richard Greil, Alden Moccia, Joseé M. Zijlstra, Bernd Hertenstein, Max S. Topp, Marianne Just, Bastian von Tresckow, Hans-Theodor Eich, Michael Fuchs, Markus Dietlein, Sylvia Hartmann, Andreas Engert, Peter Borchmann

Blood (2023) 142 (6): 553–560.

https://doi.org/10.1182/blood.2023019939

Published: 2023

Journal Articles

Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3523–3524.

https://doi.org/10.1182/blood-2022-165494

Published: 2022

Journal Articles

External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Blood (2022) 140 (Supplement 1): 777–778.

https://doi.org/10.1182/blood-2022-163454

Published: 2022

Journal Articles

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Erik Van Dijk, Jurriaan Janssen, Matias Mendeville, G. Tjitske Los-De Vries, Margaretha GM Roemer, Phylicia Stathi, Julia Richter, Yong Soo Kim, Wolfram Klapper, Ulrich Dührsen, Andreas Hüttmann, P. J Lugtenburg, Josée M. Zijlstra, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau, Bauke Ylstra

Blood (2022) 140 (Supplement 1): 9261–9263.

https://doi.org/10.1182/blood-2022-160052

Published: 2022

Journal Articles

Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study

Anna Sureda, Antonio Pinto, Herve Ghesquieres, Franck Morschhauser, Olivier Tournilhac, Pim Mutseaers, Josée M. Zijlstra, Floris A. De Jong, Tomas Janik, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 3696–3697.

https://doi.org/10.1182/blood-2022-162231

Published: 2022

Journal Articles

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Julia Driessen, Wouter J. Plattel, Lydia Visser, Anke Van Den Berg, Josée M. Zijlstra, Sanne Tonino, Gerben JC Zwezerijnen, Ronald Boellaard, Marie José Kersten, Arjan Diepstra

Blood (2022) 140 (Supplement 1): 9213–9215.

https://doi.org/10.1182/blood-2022-166120

Published: 2022

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Blood (2022) 140 (Supplement 1): 2283–2285.

https://doi.org/10.1182/blood-2022-156085

Published: 2022

Journal Articles

Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

Blood (2022) 140 (Supplement 1): 369–371.

https://doi.org/10.1182/blood-2022-163244

Published: 2022

Journal Articles

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

A.Vera de Jonge, Carolien Duetz, Wassilis S.C. Bruins, Erik D. van Werkhoven, Marcel Nijland, Marjolein W.M. Van Der Poel, Koen de Heer, Clara P.W. Klerk, Yorick Sandberg, Rob Fijnheer, Pim Mutseaers, Djamila E. Issa, Lara H. Böhmer, Roel J.W. Van Kampen, Otto J. Visser, Daphne de Jong, Josée M. Zijlstra, Tuna Mutis, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 9298–9299.

https://doi.org/10.1182/blood-2022-163068

Published: 2022

Journal Articles

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

Julia Driessen, Fer de Wit, Alex F. Herrera, Pier Luigi Luigi Zinzani, Ann S. LaCasce, Craig H. Moskowitz, Ramon Garcia-Sanz, Peter D. Cole, Michael Fuchs, Horst Mueller, Peter Borchmann, Heiko Schöder, Josée M Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten

Blood (2021) 138 (Supplement 1): 879.

https://doi.org/10.1182/blood-2021-147810

Published: 2021

Journal Articles

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Thomas Pabst, Richard Greil, Dennis A. Eichenauer, Max Topp, Marianne Just, Bernd Hertenstein, Valdete Schaub, Martin Vogelhuber, Josée M Zijlstra, Annette Plütschow, Christian Baues, Andreas Rosenwald, Markus Dietlein, Peter Borchmann, Andreas Engert

Blood (2021) 138 (Supplement 1): 2438.

https://doi.org/10.1182/blood-2021-152260

Published: 2021

Journal Articles

High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

A. Vera de Jonge, Erik D. van Werkhoven, Marcel Nijland, Koen de Heer, Marjolein W.M. Van Der Poel, Yorick Sandberg, Clara Klerk, Esther E.E. Drees, Margaretha GM Roemer, Daphne de Jong, D. Michiel Pegtel, Bronno van der Holt, Tuna Mutis, Josée M Zijlstra, Marie José Kersten, Martine E.D Chamuleau

Blood (2021) 138 (Supplement 1): 1414.

https://doi.org/10.1182/blood-2021-146812

Published: 2021

Journal Articles

Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

Jakoba J Eertink, Gerben J.C Zwezerijnen, Sanne E Wiegers, Martine E.D Chamuleau, Pieternella Lugtenburg, Daphne De Jong, Bauke Ylstra, Matias Mendeville, Ulrich Dührsen, Andreas Hüttmann, Christine Schmitz, Julia Richter, Wolfram Klapper, Otto S Hoekstra, Henrica C.W de Vet, Ronald Boellaard, Josée M Zijlstra

Blood (2021) 138 (Supplement 1): 451.

https://doi.org/10.1182/blood-2021-145855

Published: 2021

NARROW

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Improved Risk Prediction in DLBCL By Combining Clinical and PET Features with Interim PET Assessment

Important Role for Glutamine in Human and Mouse TME Models of CLL ; Towards Development of a PET Tracer As a Novel Diagnostic Tool

Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies

Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data

PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group

High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only